skip to content

Postgraduate Admissions

1 course offered in the Faculty of Biology

The course aims to select a cohort of students with the skills, motivation and ability to excel in order to create the next generation of scientific and business leaders in the therapeutics and healthcare sector.

The course is aimed at developing two types of mutually compatible future leaders:

  • Science Leaders: Those who make a decision to remain in science and will aspire to lead scientific teams, such as, but not limited to, heads of genomics, biology, therapeutic development & innovation and clinical development, either within institutions or in pharmaceutical or technology industry sector. These are the people who invent and discover the new technologies and therapies based on fundamental research.   
  • Science Hunters: These are the scientific entrepreneurs who understand Science Leaders’ innovations and who chiefly know how to transform the inventions into commercial opportunities

This highly multi-disciplinary course is co-developed and co-delivered with industry experts.

Students will develop an understanding of the mechanisms underlying normal function and subsequent dysfunction in human diseases and their amelioration or cure with advanced therapeutic regimes. The program provides students with all the tools and quantitative skills necessary to understand, develop and implement modern cutting-edge techniques in therapeutic sciences and cover the range of conventional and novel therapeutic modalities, including understanding biological pathways and therapeutic mechanisms, diagnostic and prognostic tools, identifying novel targets, and characterizing the pharmacologic profiles of new compounds, including adverse effects and toxicity. The close industry partner involvement in the development and delivery of the course sets it apart from others in the UK and indeed, internationally. Students will benefit greatly from the academic expertise and real-world insights which will be brought together in this academic-industry partnership. The course covers conventional small molecule drugs and novel therapeutics approaches such as recombinant protein technologies, gene therapy, gene editing, cell-based therapies, regenerative medicine and electroceuticals. Students will also understand the social, financial, ethical, legal and policy implications of the introduction of these new therapies, and we therefore propose to link this training very closely to industrial, entrepreneurial, clinical and regulatory activities to encourage students to consider their studies in a society-wide context.

The course is delivered by academic and industry specialists and involves a combination of formal lectures, interactive sessions, group activities, case studies and e-learning.

More Information

Department Members